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T cell immunity to Zika virus targets 
immunodominant epitopes that 
show cross-reactivity with other 
Flaviviruses
C. J. Reynolds1, O. M. Suleyman1, A. M. Ortega-Prieto1, J. K. Skelton1, P. Bonnesoeur2,  
A. Blohm1, V. Carregaro3, J. S. Silva3, E. A. James4, B. Maillère2, M. Dorner1, R. J. Boyton1 &  
D. M. Altmann1
Zika virus (ZIKV) Infection has several outcomes from asymptomatic exposure to rash, conjunctivitis, 
Guillain-Barré syndrome or congenital Zika syndrome. Analysis of ZIKV immunity is confounded by the 
fact that several related Flaviviruses infect humans, including Dengue virus 1–4, West Nile virus and 
Yellow Fever virus. HLA class II restricted T cell cross-reactivity between ZIKV and other Flaviviruses 
infection(s) or vaccination may contribute to protection or to enhanced immunopathology. We mapped 
immunodominant, HLA class II restricted, CD4 epitopes from ZIKV Envelope (Env), and Non-structural 
(NS) NS1, NS3 and NS5 antigens in HLA class II transgenic mice. In several cases, ZIKV primed CD4 cells 
responded to homologous sequences from other viruses, including DENV1–4, WNV or YFV. However, 
cross-reactive responses could confer immune deviation - the response to the Env DENV4 p1 epitope 
in HLA-DR1 resulted in IL-17A immunity, often associated with exacerbated immunopathogenesis. 
This conservation of recognition across Flaviviruses, may encompass protective and/or pathogenic 
components and poses challenges to characterization of ZIKV protective immunity.
Zika virus (ZIKV) is a Flavivirus, first discovered in 1947 in Uganda and named after the Zika Forest1–3. The cur-
rent outbreak has been associated also with a large increase in birth defects, ‘congenital syndrome associated with 
Zika virus infection’, notably microcephaly1,2.
There is a pressing need to understand innate and adaptive immune mechanisms protecting against the virus. 
Human immunity to this virus had not been extensively researched until the current outbreak and analysis has 
posed important challenges. With several Zika vaccine candidates poised to enter trials, there is an imperative 
to have agreed measurables to serve as correlates of protection4. In ZIKV infection (as indeed for most other 
Flavivirus infections) we lack the datasets of T cell response patterns that might offer us the immune correlates of 
differential outcome after exposure; this is equally true whether considering outcomes after natural exposure or 
in vaccine trials. Neutralizing antibodies, CD4 and CD8 immunity might be envisaged as important. However, 
knowledge of immunity to other related Flavivruses such as West Nile virus (WNV), Japanese encephalitis virus 
(JEV) and Dengue virus (DENV), suggests that it may be predicted that components of anti-viral antibody, CD4 
or CD8 responses could themselves be highly pathogenic5–8. The pathogenesis of both WNV and JEV infection 
encompasses T cell mediated pathology5–7. Another confounder to simple analysis of Zika virus (ZIKV) immu-
nity is the issue of virus cross-reactivity. In several of the countries in which ZIKV currently poses a threat, there 
may be as many as 10 different, related Flavivruses circulating, including DENV serotypes 1–4 and Yellow Fever 
virus (YFV), as well as YFV vaccination being widespread9. This raises important issues. First, that antigenic 
cross-reactivity has imposed a confounder for design and roll-out of reagents for unequivocal serodiagnostics 
and, therefore, for seroprevalence reporting10. Second, that the impact of anti-viral cross-reactivity has not been 
taken into account. A simple view would be that a high level of immunity in these populations to some conserved 
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or partially conserved antigen sequences may offer a degree of protection from ZIKV infection. An alternative, 
non-mutually exclusive hypothesis, is that as with antibody dependent enhancement (ADE) between DENV 
serotypes, prior immunity to related viruses may potentiate a pathogenic response to subsequent ZIKV exposure 
or vaccination (or indeed, that ZIKV immunity will alter responses to subsequent challenges with viruses such as 
DENV or YFV)4,11. Such considerations make detailed mapping of interactions between the respective anti-viral 
repertoires a priority.
Recent studies from mouse models, non-human primates and exposed humans have started to describe fea-
tures of adaptive immunity to ZIKV4,11–16. Furthermore, clues can be extrapolated from previous studies with 
other Flaviviruses17. Attempts to model acute infection in mice have encompassed neonatal or in utero infection 
of wild-type strains as well as infection of type I interferon receptor knockout strains. These models variably 
involve central nervous system (CNS) infiltration by CD4 (mainly T helper 1 (Th1)) and CD8 T cells, some-
times with associated neuropathology. In two separate studies, analysis of ZIKV CD8 IFNγ production high-
lighted an immunodominant epitope from envelope, in the region of amino acids 294–302 of the full length 
viral sequences13,14. Work by Elong Ngono and colleagues showed that murine ZIKV acute infection leads to an 
increase in activated CD8 T cells14. This response was implicated in protection since CD8 ablation exacerbated 
disease and transfer of primed CD8 T cells decreased viral load. Epitope mapping of CD8 responses by screening 
recall responses to ZIKV peptides, predicted using the www.iedb.org predictive tools, defined epitopes in Env, 
prM and NS5 proteins, including the aforementioned Env 294–302 epitope. Acute infection of rhesus macaques 
showed viral persistence at several sites including CNS (with CNS lymphocyte infiltration), CD4 and CD8 cells 
activation and a neutralizing antibody response targeted largely to envelope and NS118. A study of ZIKV immu-
nity in ZIKV-exposed humans indicated that while antigenic cross-reactivity between DENV and ZIKV was 
evident in the antibody repertoire, this was less apparent in the T cell response to Env and NS112.
We set out to put in place an initial dataset of Human leukocyte antigen (HLA) class II restricted responses 
to ZIKV epitopes that may facilitate analysis of correlates of protection. We used transgenic mouse models that 
express human class II with a particular focus on HLA-DRB1*0101 and HLA-DRB1*0401 since these alleles 
are relatively common in ZIKV exposed communities in the Americas. For example, the allele frequencies of 
HLA-DRB1*0101 and HLA-DRB1*0401 in Sao Paulo, Brazil are respectively, 0.100 and 0.119 (n = 800,809) 
www.allelefrequencies.net. Furthermore, we looked for evidence that ZIKV-primed CD4 T cells may recognize 
cross-reactive epitopes from the homologous antigens in other Flaviviruses. Using immunization of HLA class II 
transgenics with ZIKV antigen, and then acute infection of AG129 mice, we describe a large array of ZIKV CD4 T 
cell epitopes, the most comprehensive thus far. ZIKV primed T cells can in some cases respond to related epitopes 
from other Flaviviruses. However, this cross-reactive recognition can result in ‘immune deviation’ of the response 
to an altered cytokine profile of enhanced Interleukin 17 A (IL-17A). This argues for the potential of prior ZIKV 
infection or vaccination to skew subsequent immunopathogenesis on exposure to DENV.
Results
Mapping immunodominant CD4 T cell ZIKV epitopes in HLA class II transgenic mice. As a first 
step to the definition of HLA-restricted, CD4 T cell epitopes from ZIKV, we immunized transgenic mice that 
carried human class II molecules (all on an H2Aβ −/− background), with recombinant ZIKV antigens NS1, NS3, 
NS5 and Env (Table S1) and determined recall T cell responses to the full sequence as peptide 20mers overlap-
ping by 10 amino acids (Table S2). The decision to focus initial efforts on NS1, NS3, NS5 and Env was based on 
extrapolation from the ranking of immunogenicity of CD4 T cell antigens in WNV6. HLA-DR1 and HLA-DR4 
transgenics were immunized with ZIKV NS1 and recall T cell responses to the full sequence of peptide 20mers 
overlapping by 10 amino acids analysed. One CD4 epitope was identified in HLA-DR1 transgenics (p28) and one 
in HLA-DR4 (p18). Immunization with NS3 demonstrated one epitope presented by HLA-DR1 (p15) and 5 by 
HLA-DR4 (p12, 28, 29, 42, 51). Immunization with NS5 showed no HLA-DR1 epitopes and 5 HLA-DR4 epitopes 
(p22, 23, 26, 28, 29) (Table 1 and Fig. S1). We had thus shown, with respect to HLA-DR1 and DR4 restricted 
epitopes from NS1, 3 and 5, that we could define 13 epitopes, 2 from NS1, 6 from NS3, and 5 from NS5.
T cell epitopes from Env were investigated more broadly, by immunization of mice transgenic for HLA-DR1, 
DR4, DR1501 or DQ8 (Fig. 1). This enabled us to define a further 29 peptide/HLA combinations. Env was the 
most CD4 epitope-rich of the antigens. Interestingly, some epitopes were presented by more than one class II het-
erodimer: for example, Env p1 and p41 were presented by HLA-DR1, DR4, and DR1501, while p1 and p38 were 
presented by HLA-DR4, HLA-DR1501 and HLA-DQ8. The definition of epitopes that can be presented through 
both HLA-DR and HLA-DQ peptide binding grooves is interesting in light of the relatively distinct structures and 
binding pockets of these heterodimers. However, these peptides may be presented in different registers by these 
HLA transgenic strain













HLA-DR1 p28 [271–290] p15 [141–160] —
Table 1. CD4 T cell epitopes identified from the Zika virus protein antigens NS1, NS3, and NS5 in HLA-DR1, 
and -DR4, transgenic lines.
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structurally distinct heterodimers. Env p1 was here found to be presented by HLA-DR1, DR4, DR1501 and DQ8, 
as well as overlapping the sequence described by others as a mouse class I binder for stimulation of CD8 T cells. 
That is, peptide 1–20 of Env overlies the CD8 epitope previously termed 294–302 in the full viral sequence13,14. 
As might be predicted from this, the IFNγ T cell signal in our assays with p1 was found to derive both from CD4 
cells and from (endogenous class I restricted) CD8 cells (Fig. S2), despite the fact that a 20mer peptide would not 
be considered well suited to exogenous loading via the class I pathway. However, it is possible that some of the 
peptide taken up by the cell exogenously is able to be re-processed and access the class I presentation pathway.
To summarize the ZIKV T cell epitopes characterized by our approach, we identified 42 different peptide-HLA 
combinations. Of the antigens that we epitope mapped, Env was by far the most CD4 epitope-rich: taking the 
example of HLA-DR4 presentation, Env carries 2.03 CD4 epitopes for every 10 kDa protein sequence, followed 
by 0.73 for NS3, 0.49 for NS5 and 0.25 for NS1 (Table 2).
We further investigated the extent to which some of the CD4 epitopes we had defined might be broadly rec-
ognized by human T cells by conducting peptide binding assays to a panel of seven different HLA-class II het-
erodimers. The peptides tested had been identified in the HLA-DR1 transgenic line. Env p1 was also positive in 
HLA–DR4, DR1501, and DQ8 transgenics; Env p14 was also positive in HLA–DR4 transgenics; Env p41 was also 
positive in HLA-DR4 and −1501 transgenics; and Env p42 was also positive in HLA-DR1501 (Fig. 1). Each of the 
5 peptides showed moderate to high relative binding affinity to at least one of the heterodimers tested (Table 3). 
P14 and p31 showed moderate to strong relative binding affinity to almost all the HLA-class II molecules tested. 
Such peptides will be strong candidates for screening of ZIKV vaccinated cohorts, for example using ELISpot or 
class II tetramer analysis.
Figure 1. CD4 T–cell epitopes to Zika envelope protein in HLA class II transgenic mice. Mice transgenic for 
HLA-DR1 (DRB1*0101) n = 6 (A); HLA-DR4 (DRB1*0401) n = 5 (B); HLA-DR15:01 (DRB1*1501) n = 4 
(C) and HLA-DQ8 (DQB1*0302) n = 6 (D) were primed with 25 μg of recombinant zika envelope protein 
(Env). 10 days after immunisation, draining lymph node cells (DLNs) were assayed by IFNγ ELISpot for recall 
responses to the Env protein and to an overlapping panel of 50 Env peptides. Data are plotted as number of spot 
forming cells (SFC) per 106 cells for individual mice. Responses were considered positive (+) if the response 
was greater than 2 SD above the mean of the response in the absence of any antigen (shown as horizontal dotted 
line). Peptides that were defined as positive epitopes across 3 or more HLA class II transgenic mouse lines are 
highlighted.
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Cross-reactive T cell epitope recognition between ZIKV and other Flaviviruses. The T cell epitope 
sequences identified above were submitted to a BLAST search to identify other viruses containing partially 
homologous sequences. To analyse potential T cell cross-reactivity between the ZIKV epitopes and epitopes from 
other Flaviviruses, we aligned the sequences of ZIKV Env p1, p6, p7, p8, p14, p25, p29, p31, p32, p38, p41 and 
p42 against those of DENV1–4, WNV and YFV. The aligned virus sequences contained partially homologous 
sequences with an amino acid match at 3 to 17 residues out of 20. We synthesized the variant Env epitopes from 
the sequences of WNV, YFV and DENV1–4, for p1, p6, p7, p8, p14, p25, p29, p31, p,32, p38, p41 and p42 (Table 4).
We screened for potential virus cross-reactive recognition by immunization with recombinant ZIKV Env, 
then screening T cell responses by IFNγ ELISpot for recognition of the selected ZIKV epitopes or the homolo-
gous sequences from WNV, YFV or DENV1–4. This was done using mice that were transgenic for HLA-DR1, 
HLA-DR1501 or HLA-DQ8 (Fig. 2A,B,C).
HLA-DR1 transgenic mice were immunized with ZIKV Env and popliteal lymph node cells analyzed ex vivo 
at d10 by IFNγ ELISpot for response to the immunodominant epitopes p1, p14, p31, p41 and p42, or to the 
variant versions we had identified in the sequences of WNV, YFV and DENV1–4 (Fig. 2A). With respect to p1, 
we observed significant responses to the cross-reactive epitopes from WNV, YFV and DENV1–4. In the case of 
YFV, the response was low (though positive by our criteria), showing the lowest sequence identity with the ZIKV 
p1 epitope, with matches at 12 of 20 residues. Tetramer analysis confirmed the presence of HLA-DRB1*0101 
ZIKV p1 specific T cells and a high degree of cross reactivity with HLA-DRB1*0101 DENV4 p1 at the clonal 
level (Fig. S3). We also analyzed other cytokines produced during this response, to look for any indication that 
the cross-reactive peptides might act as an altered peptide ligand, with a modulated cytokine response relative to 
the ZIKV epitope. We found that the DENV4 p1 epitope (and to a lesser extent, the DENV3 p1 epitope) triggered 
an IL-17A response that was not present in the response to ZIKV p1 (Fig. 2D). Thus, stimulation of ZIKV Env 
primed T cells by the homologous DENV4 sequence shifts the response to a Th17 component. From the tools at 
www.iedb.org, the most likely minimal binding register is FVEGMSGGT (anchors underlined); considering the 
difference between the DENV4 p1 epitope and either the ZIKV or DENV1–3 epitopes, the variant residue that 
might influence T cell receptor (TCR) recognition (thereby mediating altered peptide ligand (APL) activity) is 
replacement of the methionine residue (a TCR contact), with the much smaller valine.
We defined no cross-reactive epitope recognition for the ZIKV Env p14, p31, or p42 epitopes. There was no sig-
nificant cross-reactive epitope recognition for the ZIKV Env p41. When the same experiment was done immunizing 
HLA-DR1501 transgenics with ZIKV Env, we observed cross-reactive responses to p1 from WNV, YFV, and DENV1, 
2 and 3 (Fig. 2B). There was also cross-reactive epitope recognition for the ZIKV Env immunodominant epitopes 
p25 and p41, but not for peptides p29, p32, and p42. With respect to p25, we observed significant responses to the 
cross-reactive epitopes from YFV and DENV4 and for p41 we observed significant responses to the cross-reactive 
epitopes from DENV1 and DENV3. Similar to HLA-DR1 transgenics, when Env immunized HLA-DQ8 transgenics 
were analyzed for ELISpot responses to the variant p1 peptides, significant responses were observed to each of the 
p1 variants, that is, from WNV, YFV, and DENV1–4 (Fig. 2C). There was also cross-reactive epitope recognition for 
the ZIKV Env immunodominant epitopes p7 (DENV1–4) and p8 (WNV and DENV1–3), but not for peptides p6 
and p38. Thus, T cell activation by the cross-reactive variant peptides from other Flaviviruses may be to some extent 
dependent on the presenting HLA class II allele, and may be expected to differ between individuals.
In summary, these studies show examples where HLA class II transgenic T cells, primed to respond to ZIKV 
Env, can cross-reactively respond to the partially homologous sequences from other Flaviviruses, though results 
vary depending on the presenting HLA class II heterodimer. This was seen most extensively for ZIKV Env p1. 
In the example of p1 presentation by HLA-DR1, the DENV4 epitope functioned as an APL, eliciting an IL-17A 
HLA transgenic strain
ZIKV antigen, Epitope richness (no. of epitopes 
[epitopes per 10 kDa])
Env NS1 NS3 NS5
HLA-DR4 10 [2.03] 1 [0.25] 5 [0.73] 5 [0.49]
HLA-DR1 5 [1.02] 1 [0.25] 1 [0.14] 0 [0]
Table 2. Epitope density of ZIKV proteins.
Env peptide DR1 DR3 DR4 DR7 DR11 DR15 DRB5
p1 [1–20] 638 8 118 86 >2 248 175 474
p14 [131–150] 1 250 0.2 7 0.4 0.2 1
p31 [301–320] 3 >1 129 11 1 50 53 2
p41 [401–420] 900 >1 129 114 >359 4 75 65
p42 [411–430] 319 19 >477 119 5 125 54
Table 3. ZIKV Env peptide relative binding affinity to HLA-DR molecules. Data were expressed as relative 
affinity: ratio of the half maximal inhibitory concentration of the peptide to the half maximal inhibitory 
concentration of the reference peptide. The peptide concentration preventing 50% binding of labeled peptide 
(IC50) was evaluated and data expressed as relative affinity: the ratio of the IC50 of test peptide to the IC50 of 
reference peptide. Mean ± SEM was calculated from two to three independent experiments. Relative affinities of 
10 or less were considered high binders, and relative affinities of 10–100 were moderate binders.
www.nature.com/scientificreports/
5SCIEntIFIC REPORTS |  (2018) 8:672  | DOI:10.1038/s41598-017-18781-1
Peptide name Peptide Sequence Sequence Identity
Peptide 1 variants
ZIKV P1 IRCIGVSNRDFVEGMSGGTW
WNV P1 FNCLGMSNRDFLEGVSGATW 13/20
YFV P1 AHCIGITDRDFIEGVHGGTW 12/20
DENV1 P1 MRCVGIGNRDFVEGLSGATW 14/20
DENV2 P1 MRCIGISNRDFVEGVSGGSW 16/20
DENV3 P1 MRCVGVGNRDFVEGLSGATW 15/20
DENV4 P1 MRCVGVGNRDFVEGVSGGAW 15/20
Peptide 6 variants
ZIKV P6 SNMAEVRSYCYEASISDMAS
WNV P6 ANLAEVRSYCYLATVSDLST 12/20
YFV P6 DGPAEARKVCYSAVLTNVKI 6/20
DENV1 P6 TNPAVLRKLCIEAKISNTTT 8/20
DENV2 P6 KQPATLRKYCIEAKLTNTTT 6/20
DENV3 P6 TQLATLRKLCIEGKITNITT 5/20
DENV4 P6 KEVALLRTYCIEALISNITT 8/20
Peptide 7 variants
ZIKV P7 YEASISDMASDSRCPTQGEA
WNV P7 YLATVSDLSTKAACPTMGEA 10/20
YFV P7 YSAVLTNVKINDKCPSTGEA 7/20
DENV1 P7 IEAKISNTTTDSRCPTQGEA 14/20
DENV2 P7 IEAKLTNTTTESRCPTQGEP 10/20
DENV3 P7 IEGKITNITTDSRCPTQGEA 12/20
DENV4 P7 IEALISNITTATRCPTQGEP 11/20
Peptide 8 variants
ZIKV P8 DSRCPTQGEAYLDKQSDTQY
WNV P8 KAACPTMGEAHNDKRADPAF 9/20
YFV P8 NDKCPSTGEAHLEEENEGDN 6/20
DENV1 P8 DSRCPTQGEATLVEEQDANF 12/20
DENV2 P8 ESRCPTQGEPSLNEEQDKRF 10/20
DENV3 P8 DSRCPTQGEAVLPEEQDQNY 13/20
DENV4 P8 ATRCPTQGEPYLKEEQDQQY 12/20
Peptide 14 variants
ZIKV P14 QPENLEYRIMLSVHGSQHSG
WNV P14 LKENIKYEVAIFVHGPTTVE 6/20
YFV P14 DQTKIQYVIRAQLHVGAKQE 3/20
DENV1 P14 QYENLKYSVIVTVHTGDQHQ 7/20
DENV2 P14 QPENLEYTIVITPHSGEEHA 9/20
DENV3 P14 QYENLKYTVIITVHTGDQHQ 7/20
DENV4 P14 QIENLEYTVVVTVHNGDTHA 8/20
Peptide 25 variants
ZIKV P25 ALVEFKDAHAKRQTVVVLGS
WNV P25 TLMEFEEPHATKQSVIALGS 10/20
YFV P25 HLVEFEPPHAATIKVLALGN 9/20
DENV1 P25 LLVTFKTAHAKKQEVVVLGS 15/20
DENV2 P25 TLVTFKNPHAKKQDVVVLGS 14/20
DENV3 P25 LLVTFKNAHAKKQEVVVLGS 15/20
DENV4 P25 RMVTFKVPHAKRQDVTVLGS 13/20
Peptide 29 variants
ZIKV P29 KGRLSSGHLKCRLKMDKLRL
WNV P29 TVKLTSGHLKCRVKMEKLQL 13/20
YFV P29 LYKLHGGHVACRVKLSALTL 8/20
DENV1 P29 TTTIFAGHLKCRLKMDKLTL 13/20
DENV2 P29 GNLLFTGHLKCRLRMDKLQL 13/20
DENV3 P29 GTSIFAGHLKCRLKMDKLEL 13/20
DENV4 P29 GNHMFAGHLKCKVRMEKLRI 7/20
Continued
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response not seen with the ZIKV epitope. Tetramer analysis confirmed a high degree of cross reactivity at the 
clonal level.
Antigen recognition, immunodominant epitopes and cross-reactivity in the CD4 T cell response 
to acute ZIKV infection. We next investigated ZIKV antigen and epitope recognition in the context of acute 
ZIKV infection of adult AG129 mice. Mice were infected intraperitoneally with 105 focus forming unit (FFU) 
Zika virus (PF13/251013-18) and were culled at day 7, having reached their clinical endpoint, including rapid 
weight loss and clinical signs of disease. Infected mice exhibited splenomegaly as well as marked liver abnormal-
ities. ZIKV infection was confirmed by ZIKV RNA quantification (Fig. 3A,B).
Splenic T cells were screened by IFNγ ELISpot for their response to whole ZIKV Env, NS1, NS3 and NS5 pro-
teins. A strong response was observed to Env but not to any of the non-structural proteins (Fig. 3C).
We then mapped the epitope specificity of AG129 splenic cells from d7 ZIKV infected mice. Strong Env pep-
tide specific responses were seen against p1, p31 and p36 (Fig. 3D). We next determined whether priming in the 
context of acute infection stimulated a T cell response that recognized the cross-reactive p1 epitopes from WNV, 
YFV, and DENV1–4 (Fig. 3E). Strong responses were observed to each of these epitopes, the response to the 
WNV and DENV2 epitopes being of similar magnitude to the ZIKV p1 response. In this context, the response to 
Peptide name Peptide Sequence Sequence Identity
Peptide 31 variants
ZIKV P31 KGVSYSLCTAAFTFTKIPAE
WNV P31 KGTTYGVCSKAFKFLGTPAD 9/20
YFV P31 KGTSYKMCTDKMSFVKNPTD 9/20
DENV1 P31 KGMSYVMCTGSFKLEKEVAE 10/20
DENV2 P31 KGMSYSMCTGKFKVVKEIAE 11/20
DENV3 P31 KGMSYAMCTNTFVLKKEVSE 9/20
DENV4 P31 KGMSYTMCSGKFSIDKEMAE 9/20
Peptide 32 variants
ZIKV P32 AFTFTKIPAETLHGTVTVEV
WNV P32 AFKFLGTPADTGHGTVVLEL 11/20
YFV P32 KMSFVKNPTDTGHGTAVMQV 8/20
DENV1 P32 SFKLEKEVAETQHGTVLVQV 11/20
DENV2 P32 KFKVVKEIAETQHGTIVIRV 9/20
DENV3 P32 TFVLKKEVSETQHGTILIKV 8/20
DENV4 P32 KFSIDKEMAETQHGTTVVKV 10/20
Peptide 38 variants
ZIKV P38 NSKMMLELDPPFGDSYIVIG
WNV P38 NAKVLIELEPPFGDSYIVVG 14/20
YFV P38 DDEVLIEVNPPFGDSYIIVG 11/20
DENV1 P38 EKPVNIETEPPFGESYIVVG 10/20
DENV2 P38 DSPVNIEAEPPFGDSYIIVG 11/20
DENV3 P38 DEPVNIEAEPPFGESNIVIG 10/20
DENV4 P38 NSVTNIELEPPFGDSYIVIG 15/20
Peptide 41 variants
ZIKV P41 HRSGSTIGKAFEATVRGAKR
WNV P41 HKSGSSIGKAFTTTLKGAQR 13/20
YFV P41 HKEGSSIGKLFTQTMKGAER 11/20
DENV1 P41 FKKGSSIGKMFEATARGARR 13/20
DENV2 P41 FKKGSSIGQMFETTMRGAKR 12/20
DENV3 P41 YKKGSSIGKMFEATARGARR 13/20
DENV4 P41 FRKGSSIGKMFESTYRGAKR 14/20
Peptide 42 variants
ZIKV P42 FEATVRGAKRMAVLGDTAWD
WNV P42 FTTTLKGAQRLAALGDTAWD 13/20
YFV P42 FTQTMKGAERLAVMGDAAWD 12/20
DENV1 P42 FEATARGARRMAILGDTAWD 17/20
DENV2 P42 FETTMRGAKRMAILGDTAWD 17/20
DENV3 P42 FEATARGARRMAILGDTAWD 17/20
DENV4 P42 FESTYRGAKRMAILGETAWD 16/20
Table 4. Aligned the sequences of ZIKV Env p1, p6, p7, p8, p14, p29, p31, p32, p38, p41 and p42 against those 
of DENV 1–4, WNV and YFV.
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DENV3 p1 (and to a lesser extent, DENV2 p1) yielded an APL IL-17A response not seen in response to ZIKV p1 
(Fig. 3F) although this result did not achieve statistical significance. No APL IL-10 response to ZIKV p1 variant 
peptides was seen (Fig. 3G). No cross-reactive responses were identified to ZIKV Env p31 variants (Fig. 3H).
Figure 2. T cells responding to ZIKV envelope protein peptide 1 are crossreactive with variant peptides 
from other flavivirus species. Mice transgenic for (A) HLA-DR1 (DRB1*0101) n = 6, (B) HLA-DR15:01 
(DRB1*1501) n = 6 and (C) HLA-DQ8 (DQB1*0301) n = 6 were primed with 25 μg of recombinant ZIKV 
envelope protein (Env). 10 days after immunisation, DLNs were assayed by IFNγ ELISpot for recall responses 
to the Env protein, Env peptide 10, Env peptides as shown and the corresponding peptide variants of west nile 
virus (WNV), yellow fever virus (YFV), dengue virus 1 (D1), dengue virus 2 (D2), dengue virus 3 (D3) and 
dengue virus 4 (D4). Data are plotted as number of spot forming cells (SFC) per 106 cells for individual mice. 
Responses were considered positive (+) if the response was greater than 2 SD above the mean of the response 
in the absence of any antigen (shown as horizontal dotted line). HLA-DR1 ELISpot supernatants were collected 
prior to assay development and levels of (D) IL-17A and (E) IL-10 measured by ELISA. Data shown represent 
mean ± SEM. Statistical significance was determined using an unpaired t-test.
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Discussion
While the incidence of new Zika cases in Central and South America during the 2017 rainy season has, thus 
far, been lighter than 2016, Zika infection and the associated impacts with respect to congenital Zika syndrome 
Figure 3. ZIKV virus infection in AG129 mice is associated with a strong T-cell response to ZIKV Env peptide 
1 which is crossreactive with variant peptides from other flavivirus species. AG129 mice were (i) mock infected 
(n = 4) or (ii) infected intraperitoneally with 105 FFU of ZIKV (PF13/251013-18) (n = 5). (A) Mock (grey 
circles) and ZIKV infected (black circles) mice were monitored daily for signs of weight loss and culled at 7 
days post infection. (B) ZIKV RNA load was quantified by real time PCR. Splenocytes from both groups of 
mice were assayed by IFNγ ELISpot for recall responses to (C) ZIKV proteins Env, NS1, NS3 and NS5, (D) 
an overlapping panel of 50 Env peptides and flavivirus variant peptides from west nile virus (WNV), yellow 
fever virus (YFV), dengue virus 1 (D1), dengue virus 2 (D2), dengue virus 3 (D3) and dengue virus 4 (D4) for 
peptides 1 (E) and 31 (H). Data are plotted as number of spot forming cells (SFC) per 106 cells for individual 
mice. Responses were considered positive (+) if the response was greater than 2 SD above the mean of the 
response in the absence of any antigen (shown as horizontal dotted line). ELISpot supernatants from peptide 
1 variants were also collected prior to assay development and levels of IL-17A (F) and IL-10 (G) measured by 
ELISA. Data shown represent mean ± SEM.
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continue to be a source of public health concern in more than 80 countries. Zika virus disease is notifiable in the 
USA, with more than 5000 cases notified, mainly of travelers returning from affected areas, with some hundreds 
resulting from local mosquito-borne transmission19. A very large number of candidate Zika vaccines, protec-
tive in animal models and based on diverse vaccination platforms, currently await trial4. While a number have 
already been demonstrated to confer protection from acute infection in non-human primate (NHP) challenge 
models, roll-out of Flavivirus vaccination programs can be non-trivial. Among the many issues is the fact that 
in many of the affected countries, ZIKV is one of several circulating Flaviviruses9. In some cases there is anti-
gen cross-reactivity between the viruses. Whether such cross-reactivity, either ensuing from natural infection or 
from vaccination, might confer cross-protection and/or immune potentiation of enhanced disease is uncharted. 
Furthermore, the immunocompetent animal challenge models do not, in most cases, encompass the range of 
clinical phenotypes seen in human infection, so that protection from these remains hard to evaluate. Knowledge 
of protective adaptive immune mechanisms is, thus far, based on protection from acute experimental challenge, 
whereas understanding the consequences of exposure will require understanding of the control of viral persis-
tence in diverse tissues18. At least as much as for any other virus genus, outcome after infection by Flaviviruses is 
driven be a complex interplay between viral pathogenicity and the multiple, protective or pathogenic components 
of host immunity. In any case, studies of adaptive immunity to ZIKV are in their infancy and there is a lack of any 
clear consensus of the correlates of protection.
Basic features of ZIKV protective immunity can be inferred from protective transfer studies in mice and from 
NHP vaccine studies. The data have recently been reviewed by Barouch and colleagues4. From the mouse studies, 
acute infection causes systemic activation of Natural killer (NK), CD4 and CD8 cells as well as the expected anti-
body response15. The ZIKV neutralizing antibody response has been documented and encompasses specificities 
that are cross-reactive with other Flaviviruses. Passive transfer of antibody can confer protection from acute 
challenge in the absence of a CD4 or CD8 response4. In support of the functional role of the CD8 response, CD8 
ablated mice show enhanced susceptibility, while transfer of primed CD8 cells lowers viral load14. The T cell 
cytokine profile appears IFNγ rather than IL-17A focused, and an immunodominant epitope in Env has been 
described. A number of studies have described initial ZIKV T cells epitopes by screening responses of infected 
humans or mice to candidate epitopes predicted by the predictive tools in www.iedb.org. These have included 
CD4 and CD8 epitopes in Cap, Env, NS1, 2, 3, and 512–14.
In the present study we started by immunizing mice that were endogenous class II-null but HLA transgenic 
for HLA-DR1 and DR4 with the ZIKV antigens Env, NS1, 3, or 5. Mapping the T cell epitopes within these 
antigens, we found a hierarchy of epitope density across the transgenic lines of Env > NS5 > NS3 > NS1. This 
is in contrast to epitope density in YFV vaccinees, where C > Env > NS2A = NS3 > NS120, or DENV infection, 
where C > NS3 > NS5/NS2A > Env21. Overall, we have here been able to identify forty two ZIKV T cell epitopes. 
However, we note the caveat that CD4 epitopes predicted by HLA class II transgenic studies are not always found 
identically in humans of the same HLA type. At the initiation of this program, we had based our expectations 
to some extent on what was already known about human CD4 T cell epitopes from WNV, which showed pre-
cisely the same hierarchy6. The analogy with WNV T cell immunity also serves to remind that the anti-viral T 
cell response may encompass both protective and pathogenic phenotypes. In the WNV example, patients with 
neuroinvasive disease have raised numbers of specific T cells. Furthermore, these WNV responses included 
a CXCR3 + CCR4 + CCR6- T cell population, secreting IFNγ and IL-4, highly correlated with neuroinvasive 
disease6. On the other hand, neuroinflammation in JEV infection may depend on a pathogenic Th17 response 
under poor Treg control7. In terms of antibody responses to Flavivirus epitopes, anti-DENV antibodies can confer 
potentiation of virus uptake and disease exacerbation – ‘antibody dependent enhancement’ (ADE) – with respect 
either to subsequent ZIKV or DENV infection8.
Several of the defined epitopes were in regions of sequence showing relatively high sequence conservation 
with other Flaviviruses, including WNV, DENV1–4 and YFV. We therefore took the opportunity to investigate 
cross-reactive recognition by ZIKV-primed T cells of the variant sequences from other viruses. This was done 
for the variant Env sequences from WNV, YFV and DENV1–4 for p1, p14, p31, p41 and p42 first identified in 
HLA-DR1 transgenics. Cross-reactive responses were observed with each of these specificities, most commonly 
with the WNV sequence. Peptide p1 (AA 1–20) from ZIKV Env was noteworthy since it has now been defined 
to contain an immunodominant epitope that can be presented both through class I and class II for CD4 and CD8 
responses (as we found in our Env primed mice). This Env 1–20 peptide (or core epitopes within this peptide) 
have been previously described in a number of other T cell studies, including humans infected with DENV122, 
DENV3 immunized HLA-DR3 transgenic mice23 as well as CD4 responses of DENV2 Env-immunized mice24. 
The variant Env p1–20 sequences in WNV, YFV and DENV1–4 (as well as other closely related viruses such as 
Spondweni virus) each retain the residues xxCxGxxxRDFxEGxxGxxW. It is well established in other settings 
of T cell immunity, notably autoimmune or antiviral responses, that variant stimulatory peptides may interact 
differentially with TCR contact residues, thus acting as altered peptide ligands (APL) to deviate the phenotype 
of the effector response25–28. This was indeed the case for DENV variants of p1, showing an ability not seen with 
the wild-type ZIKV sequence, to elicit an IL-17A response. This APL effect was observed both after priming with 
Env protein and after acute ZIKV infection. Indeed, this peptide encompasses an epitope that has previously been 
described as a DENV1 T cell epitope that is cross-reactively recognized with DENV222. It remains as yet unclear 
whether Th17 immunity may be neuropathogenic in ZIKV infection, as for JEV7. It might be predicted that there 
would be an increased risk of immunopathological effects if DENV infection (or vaccination) follows ZIKV infec-
tion. Th17 responses have been implicated in the immunopathogenesis of Dengue hemorrhagic fever29. Clearly, 
DENV1–4 and ZIKV show a highly overlapping distribution in Central and South America. Furthermore, there 
is potential overlap between ZIKV and WNV exposures in North America and in Asia. Possible impacts of T cell 
cross-reactivity between ZIKV and YFV merits some mention; it is unclear whether any such interaction could 
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underpin the fact that the peak of ZIKV cases in Brazil during 2016 has been followed in 2017 by the sharpest 
peak for decades of severe YFV cases30.
Our findings serve to underline the point that many of the countries that have been facing a healthcare cri-
sis of ZIKV infections are also at risk from several other, related Flaviviruses. This not only poses challenges to 
implementation of specific serodiagnsostics due to antigenic cross-reactivity, it also poses currently unanswered 
questions about the wider implications of cross-reactive immunity. At the most simplistic level, some of the 
cross-reactive overlaps may serve to confer a degree of cross-protection between infections. It could be specu-
lated that such effects may underpin the observation that in Brazil, which has very high DENV seroprevalence, 
the vast majority of ZIKV exposures during the past seasons have been asymptomatic. However, the examples of 
ADE, both within DENV exposures and, potentially, between DENV and ZIKV, along with the possibility that 
cross-reactive stimulation may deviate T cell phenotypes to a more pathogenic profile, prompts a need for greater 
efforts to characterize these relationships, as well as greater vigilance and precision in our vaccination programs 
and understanding of their true correlates of protection.
Materials and Methods
Ethics statement. Mouse experiments were performed within U.K Home Office legislation under the terms of 
Home Office Project Licenses granted for this work under the “Animals (Scientific Procdures) Act 1986”. Local ethi-
cal review and formal approval was also obtained through the Imperial College Ethical Review Process Committee.
Recombinant proteins and peptides. Sequences of the envelope protein (Env) and non-structural 
proteins NS1, NS3 and NS5 of the ZIKV were taken from a recent Brazilian isolate (GenBank accession no. 
AMH87239.1). Following codon optimisation, recombinant proteins were expressed in Escherichia coli and puri-
fied by His-Tag. The hydrophobic transmembrane domain (456–504) of Env was not included to improve pro-
tein expression, solubility and stability. (Biomatik, Cambridge, ON, Canada) (Supplementary Table 1). Synthetic 
peptides of 20 aa in length and overlapping by 10 aa were generated for each of the recombinant proteins (GL 
Biochem, Shanghai, China) (Supplementary Table 2). Flavivirus variants of Env peptides 1, 6, 7, 8, 14, 29, 31, 
32, 38, 41 and 42 for WNV (accession no. AFJ05105.1), YFV (accession no. AIZ07887.1), DENV1 (accession no. 
AKQ00039.1), DENV2 (accession no. AKQ00040.1), DENV3 (accession no. ACO06174.1) and DENV4 (acces-
sion no. AKQ00037.1) were also synthesised (Table 4).
HLA-peptide binding assays. HLA-DR heterdimers were purified from B cell lines by affinity purifica-
tion on L243. Peptide binding was evaluated with competitive ELISA using an automated workstation. HLA 
heterodimers were incubated with biotinylated indicator peptide and serial dilutions of competitor peptide. As 
reference peptides, unlabelled forms of the biotinylated indicator peptide were used to assess validity in each 
experiment. The following reference sequences were used as labelled indicator peptides, and their IC50 values 
are indicated in parentheses: HA 306–318 (PKYVKQNTLKLAT) for DRB1*01:01 (3 nM), DRB1*04:01 (45 nM), 
DRB1*07:01 (28 nM) DRB1*1101 (21 nM) and DRB5*01:01 (10 nM), MT2-16 (AAKTIAYDEEARRGLE) for 
DRB1*03:01 (50 nM) and A3 152–166 (EAEQLRAYLDGTGVE) for DRB1*15:01 (40 nM). After 24–72 h incu-
bation (37 °C), samples were neutralised with 50 μl 450 mM Tris-HCl (pH 7.5), 0.3% BSA, 1 mM DM buffer and 
applied to 96-well MaxiSorp ELISA plates (Nunc) coated with 10 μg/ml L243. Bound biotinylated peptide was 
detected by successive addition of streptavidin-alkaline phosphatase conjugate (GE Healthcare, Saclay, France) 
and 4-methylumbelliferyl phosphate substrate (Sigma, France). Emitted fluorescence was measured at 450 nm 
upon excitation at 365 nm. The peptide concentration preventing 50% binding of labelled peptide (IC50) was 
evaluated and data expressed as relative affinity: the ratio of the IC50 of test peptide to the IC50 of reference pep-
tide. Mean ± SEM was calculated from two to three independent experiments. Relative affinities of 10 or less were 
considered high binders, and relative affinities of 10–100 were moderate binders.
HLA transgenic mouse studies. This study used HLA class II transgenic mouse lines for the alleles 
HLA-DR1 (DRB1*0101), HLA-DR4 (DRB1*0401), HLA-DR1501 (DRB1*1501) and HLA-DQ8 (DQB1*0302), 
which were all maintained in the context of a homozygous knockout for murine H2-Aβ, as described previ-
ously31–36. Mice were maintained in individually ventilated cages and used in experiments as young adults. For 
T cell epitope mapping studies, mice were primed sub-cutaneously in one hind footpad with 25 μg recombinant 
protein emulsified in Hunters Titermax Gold adjuvant (Sigma-Aldrich). Ten days after immunisation the drain-
ing popliteal lymph nodes were removed and disaggregated into a single-cell suspension for ELISpot assays. The 
frequency of cells producing IFNγ in response to antigen was quantified by ELISpot using a murine IFN gamma 
ELISpot set kit (862.031.020, Diaclone; 2B Scientific, Oxon, U.K)31–36. Briefly, ELISpot plates (MSIPN4550, Merck 
Millipore, Massachusetts, USA) were coated with anti-mouse IFNγ capture antibody overnight before block-
ing with skimmed milk. Two x 105 cells, from either lymph node or spleen, plus 25 μg/ml protein or peptide 
were added to wells in HL-1 serum free medium (Lonza, Slough, U.K), supplemented with L-glutamine and 
penicillin-streptomycin (ThermoFisher Scientific, U.K). Plates were incubated for 72 h, 37 °C with 5% CO2. 
Following assay development, spots were counted on an automated ELISpot reader (Autoimmun Diagnostika, 
Strasbourg, France). Response frequencies were expressed as Δ spot forming cells (SFC) per 106 cells, with an 
epitope confirmed when the majority of immunised mice responded with a magnitude greater than the mean 
SFCs in the absence of any antigen +2 SD. Mean + 2 SD background SFC for each ELISpot is indicated by a dot-
ted line. For some experiments, supernatants from ELISpot plates were collected prior to assay development and 
levels of IL-17A and IL-10 were quantified by ELISA using paired antibodies (DY421, R&D systems, Abingdon, 
UK) and (3432-1 H, Mabtech, Nacka Strand, Sweden) for IL-17A and IL-10 respectively.
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Flow Cytometry. Draining lymph node cells from HLA-DQ8 (DQB1*0302) mice primed 11 days previously 
with 25 μg/ml ZIKV Env protein were stimulated in vitro with 25 μg/ml of the relevant peptide, in the presence of 
3 μg/ml Brefeldin A (Affymetrix eBioscience, USA) or with Brefeldin A alone. Cells were stimulated for 7 hours 
in RPMI medium supplemented with L-glutamine and Penicillin- streptomycin at 37 °C with 5% CO2. Stimulated 
cells were stained with the cell surface antibodies PE-anti mouse CD4 (clone GK1.5 from BD Pharmingen, 
USA), PE-Cy5 anti-mouse CD8a (clone 53–6.7 from Affymetrix eBioscience, USA), FITC anti-mouse CD3e 
(clone 145-2C11 from BD Pharmingen, USA) in PBS containing 10% fetal calf serum before fixation, permeabi-
lisation and intracellular antibody staining with Alexa Fluor® 700 anti-mouse IFNγγ (clone XMG1.2 from BD 
Pharmingen, USA). R-phycoerythrin (R-PE) and Allophycocyanin (APC) labelled HLA-DRB1*0101 tetramers 
loaded with either the ZIKV Env p1 or the DENV4 Env p1 variant respectively were constructed as previously 
described6,37. Labelled tetramers containing no peptide were generated for use as controls38. 1 × 106 DLN cells 
from ZIKV ENV primed HLA-DR1 transgenic mice were stained with 10 μg/ml of tetramer in 100 μl DMEM-10 
media for 2.75 hours at 37 °C. Cells were then incubated with Fc block (BD Pharmingen, USA) for 15 minutes 
on ice followed by addition of Fluorescein conjugated anti-mouse CD4 (clone:GKL5, catalogue number:100406, 
Biolegend, USA) for a further 15 minutes. Data was collected using an Attune NxT flow cytometer (Thermofisher, 
UK) and analysed using FlowJo software (FlowJo, LLC, USA).
Zika virus infection in AG129. AG129 mice were obtained from Marshall BioResources (Hull, UK). 
Animals were supplied with food and water ad libitum and monitored daily for signs of illness. Zika virus 
(PF13/251013-18, provided by European Commission Seventh Framework Program [FP7/2007-2013] for the 
DENFREE project under Grant Agreement n°282 378) was grown in C6/36 cells, and viral titers were determined 
by focus formation assay. Mice were infected intraperitoneally with 105 FFU in a volume of 100 μL. They were 
weighed and clinically scored daily to monitor disease severity. After 7 d, mice were euthanized and blood and 
spleen was collected for further analysis.
Zika virus RNA quantification. Zika virus RNA was quantified as previously described39. Briefly, RNA 
was isolated from plasma using a viral RNA extraction kit (Qiagen, UK) according to the manufacturer’s instruc-
tions and RNA was quantified using a Viia 7 real-time PCR system (Thermo Fisher Scientific, UK) using the 
TaqMan RNA-to-Ct 1-step kit (Thermo Fisher Scientific, UK). Plasmid pMA-T containing the complete 5’UTR 
of Zika virus was used for T7 polymerase in vitro transcription using the T7 Ribomax Express Large Scale RNA 
Production System (Promega, UK) and used as RNA standard.
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